FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2107-2116 May 15, 2008 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by de Lemos, J. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The incremental usefulness of adding multiple biomarkers from different disease pathways for predicting the risk of death from cardiovascular causes has not, to our knowledge, been evaluated among the elderly.

Methods We used data from the Uppsala Longitudinal Study of Adult Men (ULSAM), a community-based cohort of elderly men, to investigate whether a combination of biomarkers that reflect myocardial cell damage, left ventricular dysfunction, renal failure, and inflammation (troponin I, N-terminal pro–brain natriuretic peptide, cystatin C, and C-reactive protein, respectively) improved the risk stratification of a person beyond an assessment that was based on the established risk factors for cardiovascular disease (age, systolic blood pressure, use or nonuse of antihypertensive treatment, total cholesterol, high-density lipoprotein cholesterol, use or nonuse of lipid-lowering treatment, presence or absence of diabetes, smoking status, and body-mass index).

Results During follow-up (median, 10.0 years), 315 of the 1135 participants in our study (mean age, 71 years at baseline) died; 136 deaths were the result of cardiovascular disease. In Cox proportional-hazards models adjusted for established risk factors, all of the biomarkers significantly predicted the risk of death from cardiovascular causes. The C statistic increased significantly when the four biomarkers were incorporated into a model with established risk factors, both in the whole cohort (C statistic with biomarkers vs. without biomarkers, 0.766 vs. 0.664; P<0.001) and in the group of 661 participants who did not have cardiovascular disease at baseline (0.748 vs. 0.688, P=0.03). The improvement in risk assessment remained strong when it was estimated by other statistical measures of model discrimination, calibration, and global fit.

Conclusions Our data suggest that in elderly men with or without prevalent cardiovascular disease, the simultaneous addition of several biomarkers of cardiovascular and renal abnormalities substantially improves the risk stratification for death from cardiovascular causes beyond that of a model that is based only on established risk factors.

Source Information

From the Department of Public Health and Caring Sciences/Geriatrics (B.Z., L.B., E.I., S.B., J.Ä.), Uppsala Clinical Research Center (L.B.), and the Department of Medical Sciences (J.S., A.L., P.V.), Uppsala University, Uppsala, Sweden.

Address reprint requests to Dr. Ärnlöv at the Department of Public Health and Caring Sciences/Geriatrics, Uppsala Science Park, SE-75185 Uppsala, Sweden, or at johan.arnlov{at}pubcare.uu.se.

Full Text of this Article

Related Letters:

Multiple Biomarkers and Cardiovascular Risk
Pfister R., Hellmich M., Austin M. J., Heneghan M. A., Zethelius B., Venge P., Ärnlöv J.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:760-761, Aug 14, 2008. Correspondence

This article has been cited by other articles:

• Melander, O., Newton-Cheh, C., Almgren, P., Hedblad, B., Berglund, G., Engstrom, G., Persson, M., Smith, J. G., Magnusson, M., Christensson, A., Struck, J., Morgenthaler, N. G., Bergmann, A., Pencina, M. J., Wang, T. J. (2009). Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community. JAMA 302: 49-57 [Abstract] [Full Text]  
• Shah, S. H., de Lemos, J. A. (2009). Biomarkers and Cardiovascular Disease: Determining Causality and Quantifying Contribution to Risk Assessment. JAMA 302: 92-93 [Full Text]  
• Azuaje, F., Devaux, Y., Wagner, D. (2009). Computational biology for cardiovascular biomarker discovery. Brief Bioinform 10: 367-377 [Abstract] [Full Text]  
• Meigs, J. B. (2009). Multiple Biomarker Prediction of Type 2 Diabetes. Diabetes Care 32: 1346-1348 [Full Text]  
• Laufer, E. M., Winkens, M. H.M., Narula, J., Hofstra, L. (2009). Molecular Imaging of Macrophage Cell Death for the Assessment of Plaque Vulnerability. Arterioscler. Thromb. Vasc. Bio. 29: 1031-1038 [Abstract] [Full Text]  
• Nilsson, P. M., Boutouyrie, P., Laurent, S. (2009). Vascular Aging: A Tale of EVA and ADAM in Cardiovascular Risk Assessment and Prevention. Hypertension 54: 3-10 [Full Text]  
• Jansson, A. M., Aukrust, P., Ueland, T., Smith, C., Omland, T., Hartford, M., Caidahl, K. (2009). Soluble CXCL16 Predicts Long-Term Mortality in Acute Coronary Syndromes. Circulation 119: 3181-3188 [Abstract] [Full Text]  
• Korngold, E. C., Januzzi, J. L. Jr, Gantzer, M. L., Moorthy, M.V., Cook, N. R., Albert, C. M. (2009). Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein as Predictors of Sudden Cardiac Death Among Women. Circulation 119: 2868-2876 [Abstract] [Full Text]  
• Hagstrom, E., Hellman, P., Larsson, T. E., Ingelsson, E., Berglund, L., Sundstrom, J., Melhus, H., Held, C., Lind, L., Michaelsson, K., Arnlov, J. (2009). Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community. Circulation 119: 2765-2771 [Abstract] [Full Text]  
• Rask, K., O'Malley, E., Druss, B. (2009). Impact of socioeconomic, behavioral and clinical risk factors on mortality. J Public Health (Oxf) 31: 231-238 [Abstract] [Full Text]  
• Kastrup, J., Johansen, J. S., Winkel, P., Hansen, J. F., Hildebrandt, P., Jensen, G. B., Jespersen, C. M., Kjoller, E., Kolmos, H. J., Lind, I., Nielsen, H., Gluud, C., the CLARICOR Trial Group, (2009). High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30: 1066-1072 [Abstract] [Full Text]  
• Hlatky, M. A., Heidenreich, P. A. (2009). The Year in Epidemiology, Health Services Research, and Outcomes Research. J Am Coll Cardiol 53: 1459-1466 [Full Text]  
• Sanz, J., Moreno, P. R., Fuster, V. (2009). The year in atherothrombosis.. J Am Coll Cardiol 53: 1326-1337 [Full Text]  
• Bruno, G., Fornengo, P., Novelli, G., Panero, F., Perotto, M., Segre, O., Zucco, C., Deambrogio, P., Bargero, G., Perin, P. C. (2009). C-Reactive Protein and 5-Year Survival in Type 2 Diabetes: The Casale Monferrato Study. Diabetes 58: 926-933 [Abstract] [Full Text]  
• Bolliger, D., Seeberger, M. D., Lurati Buse, G. A. L., Christen, P., Rupinski, B., Gurke, L., Filipovic, M. (2009). A Preliminary Report on the Prognostic Significance of Preoperative Brain Natriuretic Peptide and Postoperative Cardiac Troponin in Patients Undergoing Major Vascular Surgery. Anesth. Analg. 108: 1069-1075 [Abstract] [Full Text]  
• Goldman, N., Glei, D. A., Lin, Y.-H., Weinstein, M. (2009). Improving Mortality Prediction Using Biosocial Surveys. Am J Epidemiol 169: 769-779 [Abstract] [Full Text]  
• Koenig, W. (2009). Is hsCRP Back on Board? Implications from the JUPITER Trial. Clin. Chem. 55: 216-218 [Full Text]  
• de Ruijter, W., Westendorp, R. G J, Assendelft, W. J J, den Elzen, W. P J, de Craen, A. J M, le Cessie, S., Gussekloo, J. (2009). Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338: a3083-a3083 [Abstract] [Full Text]  
• Scott, I. A (2009). Evaluating cardiovascular risk assessment for asymptomatic people. BMJ 338: a2844-a2844 [Full Text]  
• Chasman, D. I., Pare, G., Ridker, P. M (2009). Population-Based Genomewide Genetic Analysis of Common Clinical Chemistry Analytes. Clin. Chem. 55: 39-51 [Abstract] [Full Text]  
• Venge, P., James, S., Jansson, L., Lindahl, B. (2009). Clinical Performance of Two Highly Sensitive Cardiac Troponin I Assays. Clin. Chem. 55: 109-116 [Abstract] [Full Text]  
• Devarajan, P. (2008). Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injury. Nephrol Dial Transplant 23: 3737-3743 [Full Text]  
• Ridker, P. M, Paynter, N. P., Rifai, N., Gaziano, J. M., Cook, N. R. (2008). C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men. Circulation 118: 2243-2251 [Abstract] [Full Text]  
• McGeechan, K., Macaskill, P., Irwig, L., Liew, G., Wong, T. Y. (2008). Assessing New Biomarkers and Predictive Models for Use in Clinical Practice: A Clinician's Guide. Arch Intern Med 168: 2304-2310 [Abstract] [Full Text]  
• Giugliano, R. P., Braunwald, E. (2008). The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol 52: 1095-1103 [Full Text]  
• Pfister, R., Hellmich, M., Austin, M. J., Heneghan, M. A., Zethelius, B., Venge, P., Arnlov, J. (2008). Multiple biomarkers and cardiovascular risk.. NEJM 359: 760-761 [Full Text]  
• Braunwald, E. (2008). Biomarkers in Heart Failure. NEJM 358: 2148-2159 [Full Text]  
• de Lemos, J. A., Lloyd-Jones, D. M. (2008). Multiple Biomarker Panels for Cardiovascular Risk Assessment. NEJM 358: 2172-2174 [Full Text]  
• (2008). Cardiovascular Risk Prediction: Beyond the Established Risk Factors. Journal Watch Cardiology 2008: 3-3 [Full Text]  
• (2008). Multiple Biomarkers as Predictors of Cardiovascular Death. JWatch General 2008: 2-2 [Full Text]